Case Report
Accepted on 11 Jun 2025
Case report: Dose Adjustment of Orelabrutinib for Managing Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Acute Lymphoblastic Leukemia Transplantation
in Alloimmunity and Transplantation